Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GLP-1 infusion Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-response Study of Exendin-9,39 on Glucose Metabolism

NCT01218633
View directory record Official record
Conditions
Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Interventions
saline infusion, GLP-1-9,36 infusion, Exendin-9,39 at low dose, Exendin-9,39 at high dose
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
20 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 2, 2026, 7:11 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

To Determine Tolerability to Glucagon Infusion in Obese Subjects

NCT02817659
View directory record Official record
Conditions
Obesity
Interventions
Glucagon
Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

NCT02971202
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
Interventions
Hyperinsulinemic, euglycemic clamp, 20% dextrose
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years to 51 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 2, 2026, 7:11 AM EDT
Terminated Phase 2 Interventional Results available

Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery

NCT00966654
View directory record Official record
Conditions
CABG
Interventions
Placebo, GLP-1 (7-36) amide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Real-time Adaptation to Changes in Insulin Sensitivity

NCT01261052
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm, The Adaptive Proportional Derivative Algorithm
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 1 Interventional

A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake

NCT02128581
View directory record Official record
Conditions
Obesity, Diabetes, Roux-en-Y Gastric Bypass
Interventions
Exendin-9,39, Saline
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 2, 2026, 7:11 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion

NCT05264727
View directory record Official record
Conditions
Healthy, Type 2 Diabetes, Obesity
Interventions
Dextrose, Clinisol 15%
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In Vivo Assessment of Cellular Metabolism in Humans

NCT02748369
View directory record Official record
Conditions
Normal Cellular Metabolism
Interventions
Somatostatin, Glucagon
Drug
Lead sponsor
K. Sreekumaran Nair
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

NCT04466618
View directory record Official record
Conditions
Healthy, Type 2 Diabetes
Interventions
Saline, Exendin-9,39, Saline + Intralipid/Heparin, Exendin-9,39 + Intralipid/Heparin
Biological
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Not applicable Interventional Results available

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

NCT01162499
View directory record Official record
Conditions
Postprandial Hypoglycemia
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Sep 2, 2026, 7:11 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

GLP-1 and Hypoglycemia

NCT01858896
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Glucagon-Like Peptide- 1 (GLP-1) infusion, Placebo Comparator: Saline Infusion
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions
Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Action in Physiology and Diabetes

NCT02550548
View directory record Official record
Conditions
Insulin Secretion
Interventions
GIP infusion, GLP-1 infusion, Ex-9 infusion
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 2, 2026, 7:11 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 2, 2026, 7:11 AM EDT
Terminated Phase 2 Interventional Results available

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

NCT00798590
View directory record Official record
Conditions
Critically Ill, Hypoglycemia
Interventions
Glucagon-Like Peptide-1, Saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

NCT00013910
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
NNC 90-1170
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
30 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 2 Interventional Results available

Artificial Pancreas Control System in an Outpatient Setting

NCT01871870
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Artificial Pancreas Control Software
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

NCT01795144
View directory record Official record
Conditions
Monogenic Diabetes
Interventions
GLP-1, Exendin 9-39
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 2 Interventional Results available

Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients

NCT02733588
View directory record Official record
Conditions
Hypoglycemia, Complications of Bariatric Procedures
Interventions
G-Pump™ (glucagon infusion)
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 2, 2026, 7:11 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Regulation of Insulin Secretion by the GLP-1 Receptor

NCT02844907
View directory record Official record
Conditions
Insulin Secretion
Interventions
Exendin (9-39), Dexamethasone, Hyperglycemic Clamp
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 2, 2026, 7:11 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

NCT04133922
View directory record Official record
Conditions
Type 1 Diabetes, Insulin Sensitivity/Resistance
Interventions
GLP-1, Insulin, Dextrose 20 % in Water
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 2, 2026, 7:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of GLP-1 on Postprandial Lipid Metabolism

NCT01760772
View directory record Official record
Conditions
Heart Disease
Interventions
Exendin-9, GLP-1, saline
Drug · Other
Lead sponsor
David Dalessio
Other
Eligibility
40 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 2, 2026, 7:11 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

NCT06972407
View directory record Official record
Conditions
Genetic Predisposition, Type2diabetes
Interventions
Exendin 9-39, Saline
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 2, 2026, 7:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nutrient Sensing in the Duodenum

NCT01694004
View directory record Official record
Conditions
The Effect of LCFA on Nutrient Absorption
Interventions
Benzocaine Infusion into Duodenum
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 2, 2026, 7:11 AM EDT